Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis

P Garnero, T Conrozier, S Christgau, P Mathieu, P D Delmas, E Vignon

Objective: To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA.

Methods: Twelve patients with rapidly destructive and 28 patients with slowly progressive hip OA were included in a prospective, cross sectional case-control study. Urinary levels of C-terminal crosslinking telopeptide of collagen type II (CTX-II) as a marker of cartilage degradation were measured by an ELISA, and urinary free deoxypyridinoline (free DPD), a marker of bone resorption, was measured by high performance liquid chromatography. One x ray evaluation of the hips and urine samples was made in all patients when the diagnosis of OA was established.

Results: Patients with hip OA had higher mean (SD) urinary CTX-II levels than 65 healthy age matched controls (492 (232) v 342 (141), p<0.001), but no significant difference was seen for urinary free DPD (p=0.30). Increased urinary CTX-II, but not urinary free DPD, correlated significantly with decreased minimum joint space width assessed by radiograph of the hip. Mean urinary CTX-II levels were significantly higher in patients with rapidly progressive OA than in the slowly progressive group (612 (218) v 441 (221), p=0.015), whereas no significant difference of urinary free DPD was seen between the two groups (p=0.55).

Conclusion: Patients with hip OA have increased CTX-II degradation as assessed by a new urinary marker. Increased urinary CTX-II levels are associated with rapidly destructive disease, suggesting that this marker might be useful in identifying patients with hip OA at high risk for rapid progression of joint damage.

Subjects and Methods

Patients with hip osteoarthritis and healthy controls

This prospective cross sectional case-control study was conducted in 40 patients (23 women, 17 men, mean (SD) age 64 (12) years; range 44–95) who met the American College of Rheumatology criteria for primary hip OA.4 They were recruited from our outpatient clinic and included all subjects who consulted for symptomatic hip OA between 1996 and 1999. Among the 62 patients for whom two hip x ray results at a one year interval and urine samples at the second radiograph were available, 12 fulfilled the criteria for rapidly progressive hip OA.

Abbreviations: BMI, body mass index; CTXII, C-terminal crosslinking telopeptide of type II collagen; DPD, deoxypyridinoline; JSW, joint space width; OA, osteoarthritis
The remaining 28 patients had slowly progressive hip OA defined as \(<0.20\) mm joint space loss during the past year; 0.20 mm being the threshold of detection of relevant change in joint space width (JSW) with the method used in our study. All the patients were prospectively followed up in the department of rheumatology for common hip OA and were monitored for more than one year. They all had at least two pelvic radiographic examinations one year apart, showing a hip joint space narrowing progression of \(<0.2\) mm/year (mean \(-0.13\) mm/year from \(-0.20\) to \(+0.13\) mm), allowing them to be considered as slow progressors. Patients with hip OA secondarily to alternative arthropathies (that is, infectious or inflammatory arthritis, Paget's disease, aseptic osteonecrosis, and a major congenital abnormality such as congenital dislocation of the hip) were excluded. At entry a full clinical history was taken from all patients and the following information obtained: height, weight, body mass index (BMI), disease duration. Patients in the two groups were following various drug regimens of analgesics and non-steroidal anti-inflammatory drugs, but none of the patients presented clinical or radiologically detectable disease or were receiving treatment including bisphosphonates that might have interfered with the levels of urinary markers investigated in this study. Furthermore, all women were postmenopausal and none of the patients were receiving treatments that might interfere with bone metabolism, including oestrogen replacement. In each patient with hip OA, all clinical parameters, laboratory tests, and imaging (plain X-ray or MRI) were systematically investigated in this study. Moreover, all patients were healthy without any major congenital abnormality such as congenital dislocation of the hip, and between the groups with slowly and rapidly destructive disease or treatment that might interfere with bone or joint metabolism, including hormone replacement therapy in postmenopausal women.

**Radiological variables**

An anteroposterior radiograph of the pelvis was taken in patients with hip OA on the day of urine collection. A standardised procedure was used: patient in the standing position with the feet turned inward 20°, focal distance 100 cm, and beam aligned on the upper edge of the pubic symphysis. JSW at the narrowest point of the two hips was measured by a digitised image analysis method which has been previously validated. The hip most affected was considered as the target hip. Measurements were made by the same experienced observer. Briefly the radiograph to be analysed was digitised at a resolution of 600×1200 dpi (giving a pixel size of 0.004 mm) and 4096 grey levels. Subtraction and magnification were performed to obtain a very clear outline of the joint space. The joint space contours were delineated with the mouse on the superior convex margin of the femoral head and the inferior margin of the acetabulum within an angle whose summit was the centre of the femoral head (automatically given by the computer from three peripheral points drawn using the mouse) and that included the whole superior joint space from the internal boundary to the external end of the acetabulum. Intervertebral distance at the narrowest point of the joint space was automatically given by the computer.

**Biochemical measurements**

Fasting second morning void urine samples were collected in plastic containers. After mixing the whole collection, aliquots of urine were transferred into plastic tubes and frozen at \(-70\)°C without acidification. Samples were obtained from controls in the same way. All biological samples were kept frozen at \(-70\)°C until assayed.

**Molecular marker of cartilage and bone degradation**

Type II collagen degradation was assessed by measuring CTX-II using an enzyme linked immunosorbent assay (ELISA) based on a monoclonal antibody raised against a linear six amino acid epitope of the type II collagen C telopeptide. Intra- and interassay coefficients of variation are lower than 8% and 10%, respectively.

Urinary free deoxypyridinoline (free DPD) was measured on non-hydrolysed samples by high performance liquid chromatography as previously described. Intra- and interassay coefficients of variation are lower than 11% and 15%, respectively.

**Statistical analyses**

All data are expressed as mean (SD) unless otherwise specified. Distribution of urinary CTX-II and free DPD was not normal in both the healthy controls and the patients with hip OA. Consequently, urinary CTX-II and free DPD levels were logarithmically transformed before analyses. Differences in urinary CTX-II and urinary free DPD between controls and between patients with rapidly progressive and slowly progressive hip OA were assessed by unpaired Student's t test. Correlations were evaluated by linear regression analyses. Patients with a high rate of cartilage degradation were identified by separating them according to urinary CTX-II levels, using as a cut off point the mean \(+1\) SD of healthy controls, as previously suggested. Before the start of the study no data on urinary CTX-II in patients with OA were available. Retrospectively, with our sample size, we had 90% power to detect an increase of CTX-II between the overall group with hip OA and controls and between the groups with slowly and rapidly destructive hip OA at a significance level of 0.05.
RESULTS

The patients with rapidly destructive and slowly progressive hip OA, considered as a single group, did not differ from controls in age, sex distribution, and BMI (table 1). There was no significant association between urinary CTX-II or free DPD and age in either the patients with hip OA or controls (data not shown). In patients and controls urinary CTX-II correlated moderately with urinary free DPD ($r=0.47$, $p=0.002$ and $r=0.45$, $p=0.04$ in hip OA and controls, respectively). Compared with healthy controls, the 40 patients with hip OA had increased urinary CTX-II ($492 \pm 232$ ng/mmol Cr, $p<0.001$) whereas urinary free DPD excretion did not differ significantly between the two groups ($p=0.30$) (table 1).

When patients with rapidly and slowly progressive hip OA were considered separately, both groups had significantly higher urinary CTX-II levels than healthy controls ($p<0.001$ and $p=0.015$ for rapidly and slowly progressive hip OA, respectively) (table 1). Patients with rapidly progressive hip OA were older than the total population of healthy controls (table 1). When urinary CTX-II levels of patients with rapidly progressive hip OA were compared with those of a subgroup of controls matched for age ($n=41$, mean age 70 (5) years), the patients with hip OA still had significantly increased values ($612 \pm 218$ v $370 \pm 67$ ng/mmol Cr, $p<0.001$).

As shown in table 1, patients with rapidly destructive hip OA were older and had a more severe joint space narrowing than those with slowly progressive OA but did not differ in the ratio of men to women and BMI. The proportion of patients with a bilateral disease was higher (50% v 25%) in those with a rapidly destructive disease, although the difference did not reach significance ($p=0.07$).

Patients with rapidly progressive hip OA had 40% higher urinary CTX-II levels ($p=0.015$) than those with a slowly progressive disease (table 1, fig 1), whereas no significant difference was observed for free DPD levels (table 1). In the whole group of patients with hip OA, increased urinary CTX-II ($r=-0.48$, $p=0.003$), but not free DPD ($r=-0.17$, $p=0.32$), was associated with decreased minimal JSW; JSW was assessed by x-ray examination of the most affected hip on the day diagnosis was established and the day when urine samples were collected (fig 2). Patients with hip OA were then separated into those with low and high urinary CTX-II, using as a cut off point the mean + 1SD of the healthy controls. When that cut off point was used, 17/40 patients with hip OA were identified as having high urinary CTX-II levels. Among patients with a rapidly destructive disease, 9/12 (75%) had increased urinary

---

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Hip OA (n=40)</th>
<th>Control (n=65)</th>
<th>Overall hip OA v controls (P value)</th>
<th>Rapidly destructive v slowly progressive (P value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F/M)</td>
<td>7/5</td>
<td>16/12</td>
<td>0.79</td>
<td>38/27</td>
</tr>
<tr>
<td>Age (years)</td>
<td>70 (8)</td>
<td>63 (9)</td>
<td>0.03</td>
<td>63 (8)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73 (11)</td>
<td>70 (16)</td>
<td>0.85</td>
<td>69 (14)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162 (9)</td>
<td>165 (11)</td>
<td>0.49</td>
<td>161 (9)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.5 (3.4)</td>
<td>25.6 (4.2)</td>
<td>0.13</td>
<td>26.2 (3.7)</td>
</tr>
<tr>
<td>Bilateral/unilateral hip OA</td>
<td>6/6</td>
<td>7/21</td>
<td>0.07</td>
<td>–</td>
</tr>
<tr>
<td>Minimal joint space width (x ray, mm)</td>
<td>0.63 (0.67)</td>
<td>1.73 (1.24)</td>
<td>0.008</td>
<td>–</td>
</tr>
<tr>
<td>Urinary CTX-II (ng/mmol Cr)</td>
<td>612 (218)</td>
<td>441 (221)</td>
<td>0.015</td>
<td>342 (141) (&lt;0.001)</td>
</tr>
<tr>
<td>Urinary free DPD (nmol/mmol Cr)</td>
<td>3.34 (1.02)</td>
<td>3.20 (1.39)</td>
<td>0.55</td>
<td>3.5 (0.9)</td>
</tr>
</tbody>
</table>

---

Figure 1: Individual values of urinary CTX-II in patients with hip OA with a rapidly or slowly progressive disease. The dotted line represents the upper limit of the value in the 65 healthy age matched controls defined as the mean value + 1SD. The solid lines represent the mean value in each group.

Figure 2: Relationship between urinary CTX-II levels and minimal joint space width (JSW) in patients with hip osteoarthritis (OA). The left panel shows the correlation between logarithmic transformed urinary CTX-II levels (x axis) and minimal joint space width of the hip (y axis). In the right panel, patients with hip OA were categorised into those with low and high urinary CTX-II levels using as a cut off point the mean + 1SD of healthy controls. The bars represent the mean value (SEM) of the minimal JSW in patients with low or high urinary CTX-II levels.
CTX-II levels, whereas only 8/28 (29%) with a slowly progressive hip OA had high CTX-II levels ($\chi^2=5.6, p=0.015$, fig 1).

**DISCUSSION**

In this study, using a newly developed urinary molecular marker, we found that patients with hip OA had increased type II collagen degradation compared with healthy age matched controls. More importantly, among patients with hip OA, those with rapidly progressive hip OA had 40% higher levels than patients with a slowly progressive disease.

As far as we know this is the first study reporting increased type II collagen degradation in patients with hip OA using a new highly specific urinary marker. These data are in agreement with recent findings showing increased levels of urinary CTX-II in patients with knee OA. In contrast, no significant difference of urinary free DPD was found between patients with hip OA and healthy controls. Conflicting data have previously been reported for bone resorption markers in patients with OA, some studies finding increased levels, other showing no difference or even depressed levels, although most studies investigated patients with knee and not hip OA.

One of the main potential uses of biochemical markers is to identify patients at high risk for rapid progression of joint destruction. Indeed, clinical indices such as pain and physical function score are poorly related to the destruction of joint structure. When patients with hip OA were considered as a single group, we found that increased levels of urinary CTX-II were associated with decreased minimal JSW, suggesting that a sustained increased rate of type II collagen destruction, assessed by this specific urinary marker, would lead to more rapid destruction of cartilage. Such findings are corroborated by the 40% higher levels of urinary CTX-II in patients with a rapidly destructive disease than in those with a slowly progressive disease. Recent studies have shown that among different molecular markers of bone, cartilage, and synovium turnover, urinary CTX-II was the most predictive of the progression of joint damage in patients with knee OA.

We found no significant association between the urinary excretion of free DPD, a specific marker of bone resorption, and joint damage in agreement with the recent findings we obtained in patients with knee OA. Levels of bone resorption markers mainly reflect the overall skeletal change of bone resorption, which can be altered by various factors besides abnormalities of the subchondral bone turnover.

Very few studies have looked at the prognostic values of molecular markers in patients with hip OA. Serum C reactive protein, measured by a highly sensitive immunonephometry, has been reported to be increased in patients with a rapidly destructive disease. Increased serum cartilage oligomeric matrix protein and decreased levels of the tissue inhibitor of matrix metalloproteinases-1 were reported to be associated with more rapid progression of hip OA in one year studies, whereas no significant association was found with serum bone sialoprotein or hyaluronic acid. However, in these previous studies, the markers investigated were not specific for cartilage, and none of them evaluated the degradation of type II collagen molecules, which form the framework of articular cartilage.

Our study has some limitations. The most important limitation is its cross sectional design and thus we could not investigate whether baseline urinary CTX-II might predict progression of joint damage. The number of patients was limited and clearly these data need to be confirmed in larger longitudinal studies. We did not perform x ray evaluation of the knees, spine, and hands in patients with hip OA, although none had of them had symtomatic OA of these joints. Thus we could not investigate the potential contribution of these other joints to the urinary levels of the markers. Similarly, we did not perform x ray evaluation of the hips, knees, and hands of the healthy controls and did not exclude subjects with knee grade 1 spine OA because of its high prevalence in a population of that age. Consequently, we cannot exclude the possibility that some of the controls had OA. However, this would have resulted in an underestimation of the difference in urinary CTX-II levels between patients with hip OA and controls.

In conclusion, using a newly developed molecular marker, we found that patients with hip OA are characterised by increased type II collagen degradation. Increased urinary CTX-II levels were found in patients with a rapidly destructive disease, suggesting that this molecular marker might be useful for identifying patients with hip OA at high risk of rapid joint destruction.

**REFERENCES**


Garnero, Conrozier, Christgau, et al.
Type II collagen degradation in hip OA


Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

Currently, we are interested in finding contributors with an interest in the following clinical areas:

- Altitude sickness; Autism; Basal cell carcinoma; Breast feeding; Carbon monoxide poisoning; Cervical cancer; Cystic fibrosis; Ecotopic pregnancy; Grief/bereavement; Halitosis; Hodgkins disease; Infectious mononucleosis (glandular fever); Kidney stones; Malignant melanoma (metastatic); Mesothelioma; Myeloma; Ovarian cyst; Pancreatitis (acute); Pancreatitis (chronic); Polymyalgia rheumatica; Post-partum haemorrhage; Pulmonary embolism; Recurrent miscarriage; Repetitive strain injury; Scoliosis; Seasonal affective disorder; Squint; Systemic lupus erythematosus; Testicular cancer; Varicocele; Viral meningitis; Vitiligo

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
- Writing to a highly structured template (about 2000–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
- Working with Clinical Evidence Editors to ensure that the text meets rigorous epidemiological and style standards.
- Updating the text every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are health care professionals or epidemiologists with experience in evidence based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Claire Folkes (cfolkes@bmjgroup.com).
Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis

P Garnero, T Conrozier, S Christgau, P Mathieu, P D Delmas and E Vignon

doi: 10.1136/ard.62.10.939

Updated information and services can be found at:
http://ard.bmj.com/content/62/10/939

These include:

References
This article cites 24 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/62/10/939#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Calcium and bone (725)
- Clinical diagnostic tests (1282)
- Degenerative joint disease (4641)
- Epidemiology (1367)
- Musculoskeletal syndromes (4951)
- Osteoarthritis (931)
- Radiology (1113)
- Radiology (diagnostics) (750)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/